245 results about "High titer" patented technology

The invention relates to the technical field of biological medicines, and particularly discloses an anti-human CD3 rabbit recombinant monoclonal antibody as well as a preparation method and application thereof. The antibody obtains anti-CD3 immune response by immunizing a rabbit, is obtained by combining single B cell sorting, gene cloning and a mammalian cell expression system, and has high affinity and good specificity. The antibody can effectively recognize CD3 positive T cells in human peripheral blood and can be applied to the fields of flow cytometry, immunohistochemistry, T cell function research and the like. Experimental results show that the antibody has the advantages of high titer, strong fluorescence signal, low background and the like, and is superior to the traditional murine anti-CD3 antibody. Amino acid sequences of light chain and heavy chain variable regions of the antibody are further obtained, and controllability and repeatability of antibody expression are achieved. The antibody has important scientific research value and industrial application prospect, and is suitable for various scenes such as T cell marker detection, immune state evaluation, immunotherapy auxiliary research and the like.

The invention relates to the technical field of molecular biology, in particular to an avian adenovirus serum type 4 colloidal gold test strip based on a monoclonal antibody and application of the test strip. According to the invention, two monoclonal antibodies (6B3 and 8G11) aiming at FAdV4 penton protein are successfully prepared through a hybridoma technology, and both the monoclonal antibodies show high titer and strong serotype specificity. Specific analysis proves that the two monoclonal antibodies can recognize 12 FAdV4 isolates from different sources, and do not have cross reaction with other FAdV serotypes or common poultry pathogens. According to the invention, through systematic optimization of key parameters, the detection sensitivity of the test strip is 7.81 * 10 < 4 > TCID50 / 0.1 mL, and the detection time is only 15 minutes. Clinical sample verification shows that compared with an ELISA method, the total coincidence rate is 98.6%.

The invention belongs to the technical field of biochemical engineering, and particularly relates to an amitriptyline hapten and a preparation method thereof, an amitriptyline antigen and a preparation method thereof, an antibody, a kit and application. The amitriptyline hapten has a structural formula shown as a formula (I) or a formula (II). Compared with an existing structure, the amitriptyline hapten prepared by the invention has a better immune effect. The obtained antibody is high in titer, strong in specificity and high in affinity, the LOD of amitriptyline by using an Elisa method established by the antibody is 0.013 ng / mL, the IC50 of amitriptyline is 0.865 ng / mL, the quantitative detection range is 0.07-470.3 ng / mL, the detection sensitivity is high, and the linear range is wide.

The invention relates to the technical field of immune carrier microspheres, in particular to an immune carrier microsphere constructed by individualized MHC-II combined polypeptide, a vaccine and application of the immune carrier microsphere and the vaccine. A core comprises microspheres constructed by a plurality of MHC-II binding polypeptides, sequences of the MHC-II binding polypeptides are obtained based on HLA gene typing results of an inoculator, and each HLA gene corresponds to at least one high-affinity MHC-II binding polypeptide; a shell is a glucan with sulfydryl or other polymer coating layer, and sulfydryl is used as a coupling group to be connected with an antigen to construct the vaccine. The method has the advantages that competition is avoided, inhibition is generated, a better immune effect is achieved, antibodies of high-titer carrier molecules are not generated, and cross reaction side effects are avoided. The carrier molecular diversity is reduced; side effects are avoided. And antibody immunity and cellular immunity functions are generated. The particle size of the microspheres is controllable, and the immunologic function can be achieved without adjuvants. The preparation process is simple to operate and good in repeatability.

The invention discloses chicken infectious anemia virus-like particles as well as a preparation method and application thereof. The invention discloses a virus-like particle vaccine for preventing chicken infectious anemia. The virus-like particle vaccine comprises VP1 and VP2 proteins of chicken infectious anemia viruses. Chicken infectious anemia VP1 and VP2 proteins are expressed by using a baculovirus expression system, immunoblotting shows that the two proteins are successfully expressed in sf9 cells, electron microscope observation finds that the expressed proteins can be autonomously assembled into complete chicken infectious anemia virus-like particles, and the chicken infectious anemia virus-like particles have a space structure similar to that of an original virus and can be used for preparing chicken infectious anemia virus-like particles. Meanwhile, the virus-like particles have the advantages of high titer, high safety, capability of stimulating humoral immunity and cellular immunity and the like. The preparation method disclosed by the invention is simple, can be used for preparing the antigen protein of the chicken infectious anemia virus on a large scale, is high in expression quantity and short in time consumption, greatly reduces the production cost, and is suitable for large-scale production.

The invention discloses a klebsiella pneumoniae bacteriophage vBKpnPGZMUVR2301 and application thereof, and relates to the technical field of biology. The klebsiella pneumoniae bacteriophage vBKpnPGZMUVR2301 is preserved in Guangdong Microbial Culture Collection Center on October 14, 2024, the preservation address is the 5th floor of the building 59, No.100 Courtyard, Xianlie Middle Road, Guangzhou, and the preservation number is GDMCC No: 65268-B1. The bacteriophage keeps stable titer in a wide pH range (4-10) and a temperature interval (4-50 DEG C), and the highest titer can reach more than 109 pfu / mL. The bacteriophage can efficiently split klebsiella pneumoniae. The invention provides powerful technical support for developing novel antibacterial drugs and treatment schemes for klebsiella pneumoniae, and shows wide application prospect and potential clinical value.

The invention belongs to the technical field of immunodetection, and discloses a hapten and an artificial antigen for sulfonamide drug detection, a construction method and an application thereof, the structure of the hapten and the artificial antigen is shown as a formula (1): R1 =-COOH, R2 = R3 = H; r2 =-COOH, R1 = R3 = H; r3 is-COOH, and R1 is equal to R2 and H is equal to H. The invention discloses a novel sulfonamide immune hapten and a construction method of an artificial antigen of the novel sulfonamide immune hapten for the first time, and successfully obtains a specific antibody with high titer, high sensitivity and broad-spectrum recognition capability on the basis of immune animals of the artificial antigen.

The invention discloses an anti-CD3D antibody and application thereof.The antibody comprises a heavy chain variable region and a light chain variable region, the amino acid sequence of CDR-H1 of the heavy chain variable region is shown as SEQ ID NO: 4, the amino acid sequence of CDR-H2 of the heavy chain variable region is shown as SEQ ID NO: 5, and the amino acid sequence of CDR-H3 of the heavy chain variable region is GDL; the amino acid sequence of the CDR-L1 of the light chain variable region is as shown in SEQ ID NO: 6, the amino acid sequence of the CDR-L2 of the light chain variable region is as shown in SEQ ID NO: 7, and the amino acid sequence of the CDR-L3 of the light chain variable region is as shown in SEQ ID NO: 8. The anti-CD3D antibody is a rabbit monoclonal antibody, the obtained antibody is high in titer, clear in specific positioning in immunohistochemical staining and free of non-specific background staining, the antibody is wide in application, and the antibody can be used in pathological immunohistochemical staining experiments and can also be used in Western blot and flow cytometry experiments.

The invention discloses an allergen specific IgE and IgG antibody composite quality control product or calibration product as well as a preparation method and application thereof, and belongs to the technical field of biological detection. The preparation method comprises the following steps: obtaining a whole-genome sequence comprising a human IgE constant region gene sequence, a human IgG4 constant region gene sequence and a human IgG1 constant region gene sequence, and preparing a fusion protein simultaneously containing a human IgE Fc segment and a human IgG Fc segment; immunizing a healthy animal by using the allergen to obtain a purified antibody; and carrying out chemical coupling on the purified antibody and the fusion protein to obtain allergen specific IgE and IgG antibodies. By constructing allergen specific IgE and IgG antibodies, the kit can be simultaneously applied to detection of allergens IgE and IgG, has the advantages of high titer, high purity, good dilution linearity and the like, and is beneficial to improvement of diagnosis accuracy and treatment effectiveness.

The invention relates to the technical field of antibodies, in particular to antigen peptides of human PP1 alpha protein and Thr320 site phosphorylated protein of the human PP1 alpha protein, and a preparation method and application of an antibody of the antigen peptides of the human PP1 alpha protein and the Thr320 site phosphorylated protein. The invention provides an antigen peptide of human PP1 alpha protein and Thr320 site phosphorylated protein thereof, the antigen peptide has obvious advantages in the aspects of immunogenicity and the like, animals can be induced to generate high-level antibodies, and the generated antibodies have high specificity, affinity and titer. Based on the antigen peptide, the invention provides an anti-human PP1 alpha protein or a polyclonal antibody with phosphorylated Thr320 site thereof and a preparation method thereof, the polyclonal antibody has the characteristics of strong specificity, high affinity and high titer, and through immunoblotting and immunohistochemical verification, the polyclonal antibody can be used for preparing the anti-human PP1 alpha protein or the anti-human PP1 alpha protein or the anti-human PP1 alpha protein or the anti-human PP1 alpha protein or the anti-human PP1 alpha protein. The probe shows good specificity and sensitivity in detection of phosphorylation modification of human PP1 alpha protein and Thr320 site thereof, and has a good application prospect.

The invention provides an analgin hapten, a preparation method thereof, an artificial antigen, an antibody and application. The structures of the analgin haptens are as shown in a formula (I) or a formula (II), the two analgin haptens provided by the invention have spacer arms with proper lengths, and after the two analgin haptens are coupled with protein, the haptens can be fully exposed to an immune system, the spacer arms can be prevented from being recognized as much as possible, and a better antibody is generated to recognize analgin. The analgin hapten is used for preparing artificial antigen and antibody, the obtained analgin monoclonal antibody has high titer and strong specificity, an immunoassay method constructed based on the analgin monoclonal antibody has high specificity and sensitivity, analgin in a sample can be rapidly, qualitatively and quantitatively detected, the operation is simple and convenient, and the detection result is accurate and reliable.

This invention discloses a hybridoma cell line that secretes anti-polystyrene monoclonal antibodies and its applications. The hybridoma cell line includes PS-8, classified as Hybridoma cell line PS-8. The accession number for PS-8 is CCTCC NO: C2024144, the accession date is May 10, 2024, and the depositary institution is the China Center for Type Culture Collection (CCTCC), located at Wuhan University, No. 299 Bayi Road, Wuchang District, Wuhan City, Hubei Province. The hybridoma cell line provided by this invention can stably secrete anti-polystyrene monoclonal antibodies with high titer, good specificity, and high sensitivity, making it suitable for detection in reagent kits and possessing potential application value.

The application discloses an anti-human TRPS1 monoclonal antibody and a preparation method and application thereof, and belongs to the technical field of immunology. The anti-human TRPS1 monoclonal antibody provided by the application comprises VHCDR1, VHCDR2 and VHCDR3 with the amino acid sequences as shown in SEQ ID NO. 1-3, and VLCDR1, VLCDR2 and VLCDR3 with the amino acid sequences as shown in SEQ ID NO. 4-6. The nucleotide sequences of the heavy chain variable region and the light chain variable region of the monoclonal antibody, an expression cassette containing the nucleotide sequences, an expression vector, a recombinant cell and a recombinant bacterium are also provided. Therefore, the monoclonal antibody can be prepared by using genetic engineering technology, and the risk factors in the production and storage process of the traditional monoclonal antibody can be avoided. The monoclonal antibody prepared by the application has stable properties, high experimental repeatability and high titer, and has good specificity and affinity to the TRPS1 protein.

This invention discloses a broad-spectrum Staphylococcus aureus bacteriophage, SapYZUbeta, and its applications. This bacteriophage has been deposited at the China Center for Type Culture Collection (CCTCC) on May 16, 2022, with accession number CCTCC NO: M 2022629. Identification revealed that the full-length gene of this bacteriophage is 17,790 bp, and it does not contain tRNAs or genes associated with lysogenicity, virulence, or antibiotic resistance. This genetic background confirms the safety of this bacteriophage for use against foodborne pathogens and for bacteriophage therapy. Furthermore, the bacteriophage exhibits a high titer of 1.9 × 10⁻⁶. 9 The phage, with a concentration of PFU / mL, exhibits stable activity within a pH range of 3–12 and a temperature range of -80–60°C, and can be applied to various matrices. The phage provided by this invention can lyse multidrug-resistant wild-type strains isolated from different regions, including MRSA and MSSA, and is characterized by a broad lysis spectrum and high lysis efficiency.

The invention discloses a Nipah virus F protein monoclonal antibody and application thereof, the antibody comprises an antibody 2D12 and an antibody 3B10, and the Nipah virus F protein monoclonal antibody is prepared from Nipah virus F protein immunogen. The specific anti-Nipah virus F protein monoclonal antibody pair is prepared and detected, the monoclonal antibody pair can be specifically combined with the Nipah virus F protein, is high in titer and good in affinity and has neutralizing activity, and meanwhile, the detection kit prepared on the basis of the antibody pair can effectively carry out Nipah virus detection; and technical support can be provided for treatment, epidemiological monitoring and diagnosis of Nipah virus infection.

The application discloses a novel trimeric recombinant protein vaccine. Specifically disclosed are a mutant protein RBD8M with an amino acid sequence of SEQ ID No. 1 and a fusion protein of positions 26-277, positions 1-277 and SEQ ID No. 4. The application also discloses a vaccine containing the fusion protein, and further develops a trimeric recombinant protein vaccine containing the fusion protein and a double adjuvant. Experiments show that the vaccine prepared in the application can effectively induce cellular immunity and humoral immunity of the body in animals, a trace amount of the protein can stimulate a very high immune response of mice, has a good protection effect, can simultaneously produce high-titer neutralizing antibodies against various epidemic strains of the novel coronavirus, is a broad-spectrum effective new coronavirus vaccine, and has important significance for preventing novel coronavirus infection and a wide clinical application prospect.

The present application belongs to the technical field of bioengineering, and particularly relates to a Claudin18.2 gene engineering antibody based on DNA immunization and a preparation method and application thereof. The Claudin18.2 gene engineering antibody comprises a heavy chain variable region and a light chain variable region; the heavy chain variable region comprises any one of the amino acid sequences shown in SEQ ID NO. 15-16; and the light chain variable region comprises the amino acid sequences shown in SEQ ID NO. 19-20. The Claudin18.2 gene engineering antibody is obtained by immunizing Balb / c mice with full-length plasmid DNA and full-length plasmid DNA+extracellular segment polypeptide as immunogens respectively, obtaining plasma cells capable of secreting specific antibodies against Claudin18.2, and then preparing specific mouse-derived gene engineering antibodies through single-cell optical guidance technology and genetic engineering technology. The gene engineering antibodies have high titer and strong specificity, and have specific recognition ability for natural protein Claudin18.2.

This invention relates to the field of bioengineering technology, specifically to a recombinant adenovirus displaying a large antigen fragment on its capsid surface, its construction method, and its applications. The HVR1 and HVR5 regions of the hexon hypervariable region of this virus are replaced by gene fragments containing exogenous genes; each exogenous gene fragment has a flexible linker attached to both ends, and the gene sequence of the flexible linker is shown in SEQ ID No. 1. By precisely locating the naturally variable HVR1 and HVR5 loop regions exposed on the surface of the hexon protein as insertion sites, and supplementing them with flexible linkers, the core problem of exogenous sequence insertion disrupting the stability of the hexon structure is successfully solved. This allows for stable packaging to produce viral particles with high titers and infectivity, enabling the development of a new generation of highly efficient and safe capsid-displaying adenovirus vaccines.

The invention relates to a theophylline immunodetection reagent as well as a preparation method and a detection method thereof, in particular to a theophylline chemiluminescence immunodetection reagent as well as a preparation method and a detection method thereof, and the theophylline chemiluminescence immunodetection reagent comprises an anti-theophylline specific antibody and an indicating reagent for detecting an anti-theophylline specific antibody-theophylline conjugate, the anti-theophylline specific antibody is obtained by immunizing animals with theophylline immunogen. The theophylline immunogen has the beneficial effects that the theophylline immunogen has strong specificity and high immunogenicity, and the prepared anti-theophylline specific antibody has strong specificity and high titer; the chemiluminescence immunoassay reagent containing the anti-theophylline specific antibody can conveniently, rapidly and accurately determine the theophylline content in a sample, can simultaneously determine a plurality of samples on a full-automatic chemiluminescence immunoassay instrument, realizes high-flux rapid determination of theophylline, and has the advantages of high accuracy, strong specificity, high sensitivity and high sensitivity. And the accuracy and the detection efficiency are greatly improved.

The application discloses a kind of immortalization human umbilical cord mesenchymal stem cell NOTCH1-LNR overexpression stable cell line construction method and its application in liver differentiation, it is related to immortalized cell technical field.The application first connects target gene to vector, and the slow virus plasmid containing target gene is constructed, the slow virus plasmid containing target gene is introduced into 293T cell, and high titer slow virus containing target gene is generated;Immortalized human umbilical cord mesenchymal stem cell is infected with slow virus, and mixed clone cell strain is screened, and the immortalized human umbilical cord mesenchymal stem cell NOTCH1-LNR overexpression stable cell line is obtained.The application proves that the differentiation efficiency of immortalized human umbilical cord mesenchymal stem cell NOTCH1-LNR overexpression can effectively improve liver-like cell to glycogen staining and Western blotting experiment.This research result is expected to provide new technical thought for the next step development to improve the yield of MSCs liver differentiation.

The invention discloses a multi-epitope fusion protein based on porcine rotavirus VP7 and VP8 double targets as well as a preparation method and application of the multi-epitope fusion protein. According to the invention, salmonella typhimurium flagellin FliCS.T is taken as a skeleton, dominant neutralizing epitopes of VP7 and VP8 are accurately integrated, and the multi-epitope fusion antigen FliCS.T-VP7 + VP8 is constructed. The fusion protein has two immunological advantages: an FliCS.T skeleton has TLR5 adjuvant activity, so that innate immunity and adaptive immunity of a host can be efficiently activated; key neutralizing epitopes of porcine rotaviruses VP7 and VP8 are synchronously presented through a multi-epitope strategy, and high-titer specific neutralizing antibody and potent cellular immune response aiming at two structural proteins can be induced in vivo. The invention provides the multi-epitope fusion antigen of the porcine rotavirus, which integrates high immunogenicity and broad-spectrum neutralization protection, and a feasible technical scheme is provided for prevention and control of the porcine rotavirus.

Recombinant E. coli strains and synthetic protein sequence designs are leveraged for production of disordered polypeptides such as spidroins and elastin-like peptides (ELPs). These disordered polypeptides, the high-titer production of which has proven difficult, include repeating structural motifs from a small selection of amino acid residues, resulting in lack of well-defined tertiary and quaternary structure. The recombinant E. coli include expression vectors with genes encoding for the disordered polypeptide product. Expression of these genes is controlled by a promoter that downregulates and substantially inhibits basal expression in the recombinant bacteria. Further, the recombinant bacteria include mutations to one or more stress-response genes from wild-type E. coli, such as yggw, yedv, yedw, yedy, spec, speb, uspc, hcha, loip, mltc, envz, ompr, yhgf, or hupb. The recombinant E. coli enable production of high titers of disordered protein product while minimizing the toxic effects thereof on the host.

The present application relates to the technical field of HPV repair, in particular to a long-acting sustained-release device combination for treating female vaginal HPV infection and a use method thereof, which provides a safe, low-irritation and convenient-to-use drug delivery mode, and comprises a vaginal drug delivery device A and a device B used in cooperation with each other, the magnetic therapy of the vaginal drug delivery device A can promote capillary dilation and improve microcirculation, the IgY in the drug sustained-release layer of the vaginal drug delivery device A can be stably kept in the gel at a high titer, the alginate sulfate-carboxymethyl chitosan composite microemulsion makes the drug more easily gathered at the infection site, the magnetic therapy and the sustained-release drug interact with each other, promote the absorption and dissipation of inflammation, and produce a good repair environment, the functional powder dressing of the subsequent vaginal drug delivery device B is convenient for mild absorption of the exudate on the surface of the vagina after the magnetic therapy and the drug sustained-release treatment without causing discomfort, and the functional powder dressing releases various ions at a certain rate, further repairing damaged cells and tissues.

The invention discloses a silicon dioxide carrier-based HIV (Human Immunodeficiency Virus) MPER polypeptide nano vaccine as well as a preparation method and application thereof. According to the preparation method, special silicon dioxide nanoparticles are used as a carrier, and MPER polypeptide is connected to the surface of the carrier based on the atomic crystal characteristics (including large specific surface area and certain thermal stability) of the carrier, so that oligomerization of the polypeptide is reduced, and the effective antigen immunity is improved. In order to further realize the enrichment of the antigen, the MPER polypeptide is treated by adopting a four-limb peptide mode, so that a more stable system can be formed after the MPER polypeptide is coupled with the nanoparticles. Based on a stable polypeptide structure and chemical properties thereof, the polypeptide has better rigidity, the variability is reduced, the antigen quality is ensured, and the antigen activity is improved. The finally obtained nano antigen can effectively enter the body to induce a high-titer neutralizing antibody, and has great significance for controlling HIV-1 transmission.

Provided are a set of fully human TSH receptor (TSHR)-blocking monoclonal antibodies targeting a CHK36 homolog cluster, a preparation method therefor, and an application thereof. The method comprises the following steps: using flow cytometry to sort plasma cells and single memory B cells that specifically recognize TSHR in peripheral blood of a patient with a high titer of TSH-blocking antibodies (TBAb), performing in vitro cloning of antibody light and heavy chains and performing recombinant expression, and using hTSHR-CHO cells to perform screening and validation of antibody properties to obtain a blocking monoclonal antibody that specifically targets human TSHR. The fully human TSH receptor-blocking monoclonal antibodies specifically bind to a TSHR, and effectively block signal transduction after a TSH binds to a receptor, inhibit the synthetic secretion of thyroid hormones, and significantly reduce and inhibit TSHR expression and fibrosis in orbital fibroblasts of effector cells associated with thyroid-related ocular diseases. The fully human TSH receptor-blocking monoclonal antibodies have broad application prospects in the treatment of Graves' disease (GD) and other diseases caused by hyperthyroidism, such as thyroid eye disease (TED).

The present invention relates to methods for the production of high titer recombinant viral vectors, more particularly recombinant AAV vectors, so that the methods can be effectively employed on a scale that is suitable for the practical application of gene therapy techniques.

The invention relates to a high-titer influenza virus seed as well as a preparation method and application thereof, and the preparation method comprises the following steps: S1, obtaining a virus, inoculating the virus into a cell factory, and culturing to obtain a cell supernatant; and S2, carrying out microfiltration on the cell supernatant to remove cell debris in the cell supernatant, carrying out ultrafiltration concentration, and carrying out degerming filtration to obtain the high-titer influenza virus seed. According to the technical scheme, the cell factory is adopted for culturing the virus, the virus is inoculated to the ten-layer cell factory, after culturing, the cell supernatant in the cell factory is harvested, microfiltration is carried out, and the cell debris is removed, so that compared with a conventional method for removing the cell debris through centrifugation, microfiltration needs shorter time, the volume of the supernatant which can be treated at a time is larger, and the cell debris can be removed at a time. The sterile risk is lower; and concentrating the supernate, and sterilizing and filtering after concentration. The virus titer of the virus seed subjected to the preparation process can be increased by 5-10 times, and the impurity content is lower.

The invention discloses an anti-KHV ORF134 protein polyclonal antibody and application thereof, and belongs to the technical field of antibodies. The preparation method comprises the following steps: constructing recombinant plasmids by utilizing III type cyprinid herpesvirus ORF134 genes; the nucleotide sequence of the III type cyprinid herpesvirus ORF134 gene is as shown in SEQ ID NO. 4; transforming the recombinant plasmid into host bacteria, inducing protein expression, and purifying to obtain the III-type cyprinid herpesvirus ORF134 recombinant protein; a vaccine is prepared from the III-type cyprinid herpesvirus ORF134 recombinant protein, animals are immunized, and polyclonal antibody serum is obtained. The polyclonal antibody can accurately identify the III-type cyprinid herpesvirus ORF134 protein in a carp body, is high in titer and good in specificity, provides a certain theoretical basis for an immune virus prevention and control strategy, and provides basic data for developing a new detection technology.

The application belongs to the technical field of bioengineering, and particularly relates to a bacteriophage PE-2 of Escherichia coli with high blood entry efficiency and fermentation efficiency and application. The bacteriophage involved in the application has a preservation number of CCTCC NO: M20252973, and can specifically lyse pathogenic Escherichia coli O2 serotype and has high blood entry efficiency. The bacteriophage can enter blood circulation through oral administration, and can be widely distributed to the spleen, liver, heart and other tissues through blood circulation. The bacteriophage can be prepared in pilot production to obtain a very high titer, and the titer reaches 1.6x10 12 PFU / mL. Compared with the production of antibiotics, the production cost of the bacteriophage is low, and the bacteriophage provides a source and a reference example for industrial production of high-titer bacteriophage.

The application discloses an immunogen for preparing testis-specific glyceraldehyde-3-phosphate dehydrogenase lysine malonylation site-specific antibody, and belongs to the technical field of biotechnology.The immunogen is a malonylation modified polypeptide, and the amino acid sequence is IIPASTGAAKAVT, corresponding to the 278th-290th amino acid of a human GAPDHS protein, wherein a lysine at the 287th position (the 10th position in the sequence) is subjected to malonylation modification.A specific antibody designed according to the immunogen has the characteristics of high titer and high specificity. By screening a human sperm sample by using the antibody, it is found that the antibody can not only specifically recognize the GAPDHS with the lysine at the 287th position subjected to malonylation modification in vitro and in human sperm, but also is closely related to sperm forward movement and asthenozoospermia. The application has great significance in the field of preparation of reagents for precision diagnosis and treatment of idiopathic male infertility.